NORMAL SITUATION

PHARMA CHEMICALS NEDERLAND

Export PDF

Company — Normal situation.

Financial year 2023 · Closed on 31/12/2023

Net result-32,4 k €-952,8 %over 1 year
Gross margin-42,2 k €-413,4 %over 1 year
Equity153,7 k €-17,4 %over 1 year

Identity

Source · BCE/KBO

PHARMA CHEMICALS NEDERLAND is a company registered in Belgium.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0747.524.263
Legal form
Private limited company
Contributed capital
160 000,00 €
Latest accounts
31/12/2023
Signals
Solid equity

Financials

Source · NBB, 3 filings

Trend over 3 financial years

202320222021
Income statement
Gross margin-42,2 k €13,5 k €33,5 k €
EBITDA-42,2 k €13,1 k €32,7 k €
Operating result-32,4 k €5,1 k €29,9 k €
Net result-32,4 k €3,8 k €22,3 k €
Balance sheet
Equity153,7 k €186,2 k €182,3 k €
Total assets153,7 k €194,9 k €189,8 k €
Cash38,6 k €67,9 k €70,2 k €
Debts–8,7 k €7,5 k €

Board of directors

Source · NBB, accounts to 31/12/2023

2 active · 1 ended

Active mandates

Pharmentum

Director · 0699.939.132

Represented by Michaël Hillaert

Active
TLYS

Director · 0712.615.151

Represented by Tieme Leyseele

Active

Ended mandates

Aarab Holding

Director · 0749.607.189

Represented by Saïd Aarab

Ended

Full financial information

Source · NBB
202320222021
Type of accountAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202301/01/202220/05/2020
Closing of the financial year31/12/202331/12/202231/12/2021
Length of the financial year12 months12 months20 months
Filing date30/08/202431/08/202330/08/2022
General meeting20/06/202415/06/202316/06/2022
Currency of the financial yearEUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 3 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202320/06/202430/08/2024FrenchPDF
Abridged model31/12/202215/06/202331/08/2023FrenchPDF
Abridged model31/12/202116/06/202230/08/2022FrenchPDF

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2023

2 active · 1 ended

Active mandates

Pharmentum

Director · 0699.939.132

Represented by Michaël Hillaert

Active
TLYS

Director · 0712.615.151

Represented by Tieme Leyseele

Active

Ended mandates

Aarab Holding

Director · 0749.607.189

Represented by Saïd Aarab

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Dissolution10/03/2025
    RUBRIQUE FIN (CESSATION, ANNULATION CESSATION, NULLITE, CONC, REORGANISATION JUDICIAIRE, ETC...) - RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
    PDF
  • Restructuring22/04/2024
    RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
    PDF
  • Mandates03/07/2020
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - DEMISSIONS, NOMINATIONS
    PDF
  • Other25/05/2020
    RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2023
    Annual accounts 2023-32,4 k €↓
  2. 2022
    Annual accounts 20223,8 k €↓
  3. 2021
    Annual accounts 202122,3 k €